Archived explainer. For the current picture see today's ATAI page.
ATAIBECKLEY INC (ATAI) is moving -0.42% in the latest session. Our newswire has captured 3 stories on ATAI across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
ATAI stock is moving lower by 0.42% to $7.19 in early trading. The decline follows a series of downgrades from key Wall Street firms, including H.C. Wainwright and Berenberg, who cited limited near-term upside due to the company's pending acquisition by Eli Lilly. The stock opened with a 0.8% gap down from the prior close and has since traded in a narrow range.
The downgrade activity reflects broader investor skepticism about ATAI's prospects following the $3.8 billion deal with Eli Lilly. H.C. Wainwright and Guggenheim both reduced their ratings to Neutral, while Jefferies cut its stance to Hold. These moves come after Cathie Wood's ARKG sold 1.12 million ATAI shares last week, though the fund still holds a significant stake of 3.19 million shares. The stock had surged to a 52-week high last week amid a broader rotation into biotech and growth sectors, but the recent downgrades have shifted sentiment.
Insider transactions also highlight ongoing selling pressure. Three insiders, including the Chief Medical Officer and COO, have sold shares in the last 30 days, totaling $938K. The most recent filing was on July 9, 2026, according to SEC data.
ATAI has traded between $2.67 and $7.22 over the past 52 weeks. The stock opened at $7.17, with a session high of $7.21 and a low of $7.10. Trading volume has reached 21.3 million shares, which is 2.4 times the 3-month average. The stock has gained 35.3% over the last 8 sessions, climbing from $5.32 to $7.20. However, the recent downgrades and insider selling may weigh on momentum.
The stock is currently unprofitable with an EPS of -2.44 for the trailing twelve months, but revenue has grown by 87.2% over the same period. Investors should monitor the broader market reaction to the Eli Lilly acquisition and any changes in analyst coverage.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.
Investors rotated into biotech, cybersecurity and insurance stocks with stronger growth prospects and earnings strength.
More on ATAI: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ATAI move explainers: 2026-07-21 · 2026-07-20 · 2026-07-17 · 2026-07-16